These results indicate that triazolo–thiadiazoles attenuate the ability of blood-borne carcinoma cells to extravasate through the subendothelial basement membrane, attributed to their ability to inhibit heparanase enzymatic activity, ECM degradation, and cell invasion. This evidence concerns the gene HPSE and carcinoma.